Presents further validation of the Robust Immune Response from a combination of MVP-S with checkpoint ...
Announced the acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, ...
Announces today that they have entered into a Research Agreement to develop mRNA-based Rabies, Leptospirosis, ...
Announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination ...
Announces positive preliminary results from the PESCO study, an investigator-initiated, open-label, ...
Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile...
Announces highly promising results from a two-arm phase 1 clinical study of the safety and immunogenicity ...
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company...
Provides a summary of operating initiatives over the past year following the integration of the DPX™ ...
Announces positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S") along with neoadjuvant ...